



**GlaxoSmithKline**

PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel. 919 483 2100  
[www.gsk.com](http://www.gsk.com)

**GlaxoSmithKline has taken important steps to reduce the use of chlorofluorocarbons (CFCs) – SEREVENT® (salmeterol xinafoate) Inhalation Aerosol is no longer available starting June 2003**

Dear Healthcare Professional:

As you may know, SEREVENT Inhalation Aerosol is in the process of being phased out as part of the GlaxoSmithKline commitment to reducing the production of CFC-containing metered-dose inhalers. These actions are consistent with the Montreal Protocol, a global agreement to protect the ozone layer.

GlaxoSmithKline has now ceased production and distribution of SEREVENT Inhalation Aerosol. **Please note that this phaseout applies only to the Inhalation Aerosol formulation of SEREVENT.** We anticipate that SEREVENT Inhalation Aerosol will no longer be available starting in June 2003.

For more information about the phaseout of SEREVENT Inhalation Aerosol, please call GlaxoSmithKline at 1-800-340-3236.

Sincerely,

A handwritten signature in black ink that reads "Kathleen Rickard MD".

Kathleen A. Rickard, MD  
Vice President  
Respiratory Clinical Development and Medical Affairs, North America